Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8972077 | 0.83 | CA1 (0.33) | RAPGEF4L3MBTL1CA1CA2MEN1 | |
| SCHEMBL21433771 | 0.71 | ALOX5 (0.32) | RAPGEF4CA1CA2KMT2AALDH1A1 | |
| SCHEMBL29179097 | 0.70 | RAPGEF4 (0.74) | RAPGEF4L3MBTL1CA1CA2KDM4E | |
| SCHEMBL4316973 | 0.70 | RAPGEF4 (0.65) | RAPGEF4L3MBTL1CA1CA2KDM4E | |
| SCHEMBL30877502 | 0.69 | RAPGEF4 (0.63) | RAPGEF4L3MBTL1CA1CA2KDM4E | |
| SCHEMBL15175998 | 0.69 | RAPGEF4 (1.00) | RAPGEF4L3MBTL1CA1CA2KDM4E | |
| SCHEMBL21433773 | 0.68 | ALOX5 (0.35) | — | |
| SCHEMBL6259796 | 0.68 | RAPGEF4 (0.70) | RAPGEF4L3MBTL1CA1CA2KDM4E | |
| SCHEMBL15754560 | 0.68 | CA1 (0.35) | CA1CA2 | |
| SCHEMBL5534938 | 0.67 | RAPGEF4 (0.74) | RAPGEF4L3MBTL1CA1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9417245-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150153350-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-8980565-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8546088-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120245508-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-09-27 | — | — | US | disclosed |
| US-20120244551-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-09-27 | — | — | US | disclosed |
| US-8207329-B2 | Synthesis of chlorins and phorbines with enhanced red spectral features | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8187824-B2 | Porphyrinic compounds for use in flow cytometry | NORTH CAROLINA STATE UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-10 | — | — | US | disclosed |
| US-20090075295-A1 | PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227553-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | CRY1, CRY2, HCCS | RAPGEF4 2368/4885L3MBTL1 4873/4885CA1 2283/4885 |
| US-20120245508-A1 | SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES | CRY1, CRY2, QDPR | RAPGEF4 2241/4885L3MBTL1 4872/4885CA1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.